linjc16/ctgov huggingface dataset:
Early Dieting in Girls: a Longitudinal Cohort Study

Study Overview
=================
Brief Summary
-----------------
This longitudinal observational cohort followed the growth and development of non-Hispanic white girls from age 5 to 15 years, with a focus on the development of the controls of food intake.

Detailed Description
-----------------
This longitudinal observational cohort followed the growth and development of non-Hispanic white girls from age 5 to 15 years, with a focus on the development of the controls of food intake. Data was collected biennially from girls and their mothers and fathers. Measures included anthropometrics, questionnaires and laboratory measures of eating behavior, dietary recalls, psychosocial characteristics, and parenting measures.

Official Title
-----------------
Early Dieting in Girls

Conditions
-----------------
Eating Behavior, Dietary Habits, Weight, Body

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Living with both biological parents Exclusion Criteria: Severe food allergies Chronic medical conditions affecting food intake

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Early Dieting in Girls cohort<br>A cohort of 197 non-Hispanic white girls, observed from age 5 to age 15 years | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dieting practices | Derived from questionnaire by French et al. | Pattern of development from age 5 to 15 years | 
| Dietary restraint | Dutch Eating Behavior Questionnaire | Pattern of development from age 5 to 15 years | 
| Disinhibition | Dutch Eating Behavior Questionnaire | Pattern of development from age 5 to 15 years | 
| Disordered eating | Children's Eating Attitudes Test/Eating Attitudes Test | Pattern of development from age 5 to 15 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body mass index | Weight in kg/height in meters squared, converted to z-scores using CDC growth charts | Age 5, 7, 9, 11, 13, and 15 years | 
| Total body bone mineral content | Dual energy x-ray absorptiometry | Age 9, 11, 13, and 15 years | 
| Dietary intake | 3-24 hour dietary recalls | Age 5, 7, 9, 11, 13, and 15 years |
Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children

Study Overview
=================
Brief Summary
-----------------
ANGPTL3 and ANGPTL8 are emerging molecules involving lipid metabolism. In previous in vivo study using mice, ANGPTL8 regulated the activation of ANGPTL3 which was known to inhibit lipoprotein lipase activity and stimulate lipolysis of adipose tissue. Besides, glypican 4 was identified as a novel adipokine modulating adipocyte differentiation. Thus, the investigators postulated that different serum concentrations of ANGPTL3, ANGPTL8 and glypican 4 might affect progression of obesity in children. The investigators measure these molecules in Korean children, and investigate the association between these molecules and development of obesity.

Detailed Description
-----------------
Participants in this study were selected from the Korean Metabolic disorders & Obesity Study in Elementary School children (KMOSES), the main aim of which was to comprehensively assess obesity-related metabolic risk factors and to evaluate clinical outcomes in Korean children prospectively. Korean children who were participated in a school-based health examination, were reexamined for the 3-year follow-up assessment.

Official Title
-----------------
Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children: a Three Year Prospective Cohort Study

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants who were reexamined for the 3 year follow-up assessment Exclusion Criteria: Participants who were not being available for the 3 year follow up assessment

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The changes of body mass index according to serum level of ANGPTL3, ANGPTL8 and glypican 4 |  | Baseline and 3 years |
Oxytocin Antagonist in Patients With Repeated Failure of Implantation

Study Overview
=================
Brief Summary
-----------------
In this study the investigators compare the usual way of embryo transfer (without medication) with an embryo transfer while administering oxytocine antagonist. This to improve implantation and increase the pregnancy rate.

Official Title
-----------------
Oxytocin Antagonist in Patients With Repeated Failure of Implantation. A Prospective Randomized Placebo-controlled Double-blind Study.

Conditions
-----------------
Implantation Failure

Intervention / Treatment
-----------------
* Drug: Atosiban
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IVF/ ICSI patients below 38 years 2e to 6e IVF-cycle Exclusion Criteria: patients with endocrinological diseases or problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Atosiban<br>Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours. | Drug: Atosiban<br>* Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.<br>|
| Placebo Comparator: placebo<br>Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| implantation rate | the number of patients that show a positive serum blood pregnancy test | 16 days from eggretrieval | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rate | The number of patients with an ongoing first trimester pregnancy | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
repeated implantation failure (RIF), atosiban, pregnancy
Antiphospholipid Antibodies and Fetal Growth Restriction

Study Overview
=================
Brief Summary
-----------------
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of fetal growth restriction (diagnosed postpartum), but this was done without solid evidence of a relation between the two or using the most common form of fetal growth restriction diagnosis (ultrasound). Our study will try to add information to this particular point.

Official Title
-----------------
Antiphospholipid Antibodies and Early Fetal Growth Restriction (<34 Weeks of Gestation). A Case Control Study.

Conditions
-----------------
Fetal Growth Restriction, Antiphospholipid Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational age between 24-34 weeks. Ultrasonographic evidence of fetal growth restriction Abdominal circumference < 3rd percentile. Doppler with increase of placental resistance. Exclusion Criteria: Known antiphospholipid syndrome. Known presence of antiphospholipid antibodies. Patients with systemic lupus erythematosus.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases<br>Patients with ultrasonographic diagnosis of fetal growth restriction. | |
| Control<br>Patients with normal pregnancies at term. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lupus anticoagulant | Number of cases positive for Lupus Anticoagulant. | 8 months | 
| Anticardiolipin antibodies | Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies. | 10 months | 
| B2 Glycoprotein I | Number of cases with levels of B2 Glycoprotein I > 99% | 10 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antibodies, anticardiolipin, Antibodies, B2 Glycoprotein I, Lupus Anticoagulant, Fetal Growth Restriction
Wide Use of Paperless Partograph in Evaluation of Labour

Study Overview
=================
Brief Summary
-----------------
Paperless partograph wide using in labour room as simple tool in evaluation of labour

Detailed Description
-----------------
Both world health organization ( WHO) PARTOGRAPH and modified world heath organization (WHO)PARTOGRAPH are too long labour tools in evaluation of labour so we need simple tool in evaluation of labour

Official Title
-----------------
Wide Using of Paperless Partograph in Evaluation of Labour

Conditions
-----------------
Labor Complication, Labor Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Spontaneous labour cephalic presentation pregnant 37 weeks up to full term Exclusion Criteria: mail_presentation induced labour

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progress of labour | Cervical dilated 1 cm each hour | up to 2 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New born | Apgar scor at 1 minute and Apgar scor at 5 minutes | up to 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pregnancy.obstructed labour
High Ankle Block Versus Regional Block for Acute Pain Control After Ankle Surgery

Study Overview
=================
Brief Summary
-----------------
Researchers are trying to determine if a high ankle block during ankle surgery provides the same pain relief as the standard regional block.

Detailed Description
-----------------
Participants scheduled for elective ankle surgery will be randomized to have either a high ankle nerve block or a regional nerve block. Pain levels after surgery will be assessed to determine whether one type of block provides better pain relief compared to the other.

Official Title
-----------------
High Ankle Block Versus Regional Block for Acute Pain Control After Ankle Surgery: A Prospective Randomized Controlled Study

Conditions
-----------------
Ankle Surgery

Intervention / Treatment
-----------------
* Procedure: Nerve block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Adults undergoing elective foot and ankle surgery Adults ≥18 years, intact presurgical peripheral sensation based on 5.07 monofilament testing, foot and ankle surgery Exclusion Criteria Presurgical neurologic discrepancies (peripheral neuropathy, radiculopathy) Complex regional pain syndrome peripheral nerve surgery Surgery above the level of the tibiotalar joint Narcotic dependency Anyone unable to receive a high ankle block

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Single shot regional popliteal and saphenous block<br>Standard of care traditional single shot popliteal / saphenous regional block for acute pain control after elective ankle surgery | Procedure: Nerve block<br>* High ankle nerve block<br>|
| Experimental: High ankle block<br>High ankle block for acute pain control after elective ankle surgery | Procedure: Nerve block<br>* High ankle nerve block<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pain score | Measured using Defense and Veterans Pain Scale (lowest score of 0 = No pain and 10 = As bad as it could be, nothing else matters) | 24 hours, 48 hours, 72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nerve block
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.

Official Title
-----------------
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of VQW-765 in Patients With Performance Anxiety

Conditions
-----------------
Performance Anxiety

Intervention / Treatment
-----------------
* Drug: VQW-765
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability and willingness to provide written informed consent. Sufficiently fluent in English to participate in the trial. Male and female patients aged 18-70 years (inclusive). Exclusion Criteria: Lifetime history of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders or obsessive-compulsive disorder. Current or planned pregnancy or nursing during the trial period. A positive test for substances of abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VQW-765<br> | Drug: VQW-765<br>* oral capsule<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* oral capsule<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective Units of Distress Scale (SUDS) |  | 1 Day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinician Global Impression of Change (CGI-C) scale at visit 2 |  | 1 Day | 
| Patient Global Impression of Change (PGI-C) scale at visit 2 |  | 1 Day | 
| Assessment of safety and tolerability of a single dose of VQW-765, as measured by spontaneous reporting of adverse events (AEs) |  | 1 Day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
social phobia, social anxiety disorder
Vitrification for Ovarian Tissue Harvesting

Study Overview
=================
Brief Summary
-----------------
Increasing interest has emerged concerning ovarian tissue cryopreservation and subsequent transplantation as a potential way of preserving fertility in cancer patients as well as for women who just wish to delay childbearing. As the majority of existing protocols use the slow freezing method, this study aims to test vitrification techniques of ovarian cortex.

Official Title
-----------------
Testing of Vitrification Protocols for Ovarian Tissue Harvesting in Female to Male Transsexuals

Conditions
-----------------
Ovary; Anomaly

Intervention / Treatment
-----------------
* Other: Vitrification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female-to-male transsexuals gender completing operation signed informed consent form willingness to donate ovarian tissue for research purposes age >=18 years Exclusion Criteria: malignant disease age under 18 years refusal to donate ovarian tissue

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: Vitrification of ovarian tissue
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Vitrification|Vitrification of ovarian tissue|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival of ovarian tissue | histologic and enzymatic evaluation of ovarian tissue with respect to survival and functionality of ovarian follicles | 2 days until 2 years after freezing |
Spinal Anesthesia - Intraocular Pressure

Study Overview
=================
Brief Summary
-----------------
We aim to investigate the effect of spinal anesthesia on intraocular pressure.

Detailed Description
-----------------
Spinal anesthesia provides adequate anesthetic conditions for many operations. These operations include orthopedic, urological, gynecological and many general surgery operations. Although few, side effects of the procedure and its effects on body are well known. However, there is inadequate knowledge about the effects of spinal anesthesia on pressure changes in the eyes. These pressure changes in eyes can result in some detriments. Elevated pressures in the eyes can result in disease known as glaucoma, that makes hazard to eyes. Decreased eye pressures can also result in some eye detriments. We aimed to investigate the effects of spinal anesthesia procedure on eye (intraocular) pressure changes.

Official Title
-----------------
Intraocular Pressure Changes After Spinal Anesthesia: Acute and Subacute Effects

Conditions
-----------------
Intraocular Pressure

Intervention / Treatment
-----------------
* Other: Spinal anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients having general surgery operations under umbilicus patients of American Society of Anesthesiologists (ASA) status I-II Exclusion Criteria: patients denying spinal anesthesia contraindications for spinal anesthesia eye diseases hypertension ASA status III or more

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Spinal<br>Spinal anesthesia for surgical procedure will be applied to the patients. Intraocular pressures will be measured before and after the procedure. | Other: Spinal anesthesia<br>* Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of the patients with changed intraocular pressure |  | One month |
Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
The investigators will compare tumor marker levels, including PSA, in samples taken from a peripheral upper limb vein and the internal iliac veins. These will be collected from patients who are scheduled for prostatectomy as part of their standard of care for prostate cancer. A selective internal iliac vein sampling procedure will be performed in Interventional Radiology. Venous samples will be correlated with prostatectomy specimens. The aim is to predict the side of the prostate containing tumor.

Official Title
-----------------
Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Other: Obtaining biospecimen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All male patients, age 18 to 99, with biopsy proven prostate adenocarcinoma prior to planned radical prostatectomy. Informed Consent/HIPAA Form discussed and signed by subject. Baseline lab values obtained within 120 days of planned selective venous sampling. Exclusion Criteria: Skin related problems around the planned venepuncture site (infection, phlebitis, scars) Documented allergy to iodinated contrast or lidocaine. Coagulopathy with an INR of greater than 1.5 Thrombocytopenia with platelets less than 25,000 uL Renal insufficiency with a creatinine of 1.5 mg/dL Documented current upper extremity or central venous thrombosis DRE within 4 weeks prior to selective venous sampling Prostate biopsy within 6 weeks prior to selective venous sampling. Patient unable to sign his own consent or does not demonstrate full understanding of the procedure. Patient has known metastatic disease or a known primary cancer other than prostate adenocarcinoma. Patient has already been enrolled in this research study. Life expectancy less than 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Selective internal iliac vein sampling<br> | Other: Obtaining biospecimen<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Adverse Events |  | 1 year |